Rheumatology (Oxford, England) · 2025
An exploratory trial of a single dose of CAM2043 (treprostinil subcutaneous depot) in SSc-related RP.
СтатьяКлиническое исследование II фазыПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Herrick Ariane L, Murray Andrea, Dinsdale Graham, Manning Joanne, Chukwu Chukwuma, Alvarez Fernandez Marcia, Axling Ulrika, Seibold James R, Tiberg Fredrik
Аннотация
OBJECTIVES: Our aim was to explore the effect of a single subcutaneous dose of CAM2043, a novel extended-release subcutaneous formulation of treprostinil, on finger temperature in patients with SSc-related RP.
METHODS: This was an exploratory, open-label, single-dose Phase 2 trial. Ten female patients (median age 54.0 years) attended on six occasions: screening, baseline (day 1), days 2, 3, 8 and 15. On day 1, patients received a single subcutaneous injection of 2.5 mg CAM2043. A standard cold challenge test of the hands was performed pre-dose and at 3, 6, 24, 72, 168 and 336 h post-dose, with temperature response over the subsequent 15 min measured by infrared thermography. The primary end point was the mean change in area under the temperature-time curve (AUCtherm) for rewarming (eight fingers) at 6 h vs baseline.
RESULTS: AUCtherm increased 6 h post-dose (mean increase 192.7°C×sec [95% CI: -727.1, 1112.6]) and was significantly greater at 24 h than at baseline (mean increase 1175.8°C×sec [95% CI: 127.3, 2224.3]), returning to baseline values by day 15. Maximum temperature after rewarming increased significantly from baseline at 24 h, by 1.4°C (95% CI: 0.1, 2.7). Mean (S.D.) Raynaud's Condition Score (3.7 [1.3] units at baseline) improved significantly post-dosing, including day 8 (mean reduction 1.6 units [95% CI: -2.68, -0.52]). Adverse events were reported by all 10 patients: all reported erythema and pain at the injection site.
CONCLUSION: The positive outcome indicates that CAM2043 could be further investigated in clinical trials of RP.
TRIAL REGISTRATION: www.clinicaltrialsregister.eu/, EudraCT number 2019-002444-24.
METHODS: This was an exploratory, open-label, single-dose Phase 2 trial. Ten female patients (median age 54.0 years) attended on six occasions: screening, baseline (day 1), days 2, 3, 8 and 15. On day 1, patients received a single subcutaneous injection of 2.5 mg CAM2043. A standard cold challenge test of the hands was performed pre-dose and at 3, 6, 24, 72, 168 and 336 h post-dose, with temperature response over the subsequent 15 min measured by infrared thermography. The primary end point was the mean change in area under the temperature-time curve (AUCtherm) for rewarming (eight fingers) at 6 h vs baseline.
RESULTS: AUCtherm increased 6 h post-dose (mean increase 192.7°C×sec [95% CI: -727.1, 1112.6]) and was significantly greater at 24 h than at baseline (mean increase 1175.8°C×sec [95% CI: 127.3, 2224.3]), returning to baseline values by day 15. Maximum temperature after rewarming increased significantly from baseline at 24 h, by 1.4°C (95% CI: 0.1, 2.7). Mean (S.D.) Raynaud's Condition Score (3.7 [1.3] units at baseline) improved significantly post-dosing, including day 8 (mean reduction 1.6 units [95% CI: -2.68, -0.52]). Adverse events were reported by all 10 patients: all reported erythema and pain at the injection site.
CONCLUSION: The positive outcome indicates that CAM2043 could be further investigated in clinical trials of RP.
TRIAL REGISTRATION: www.clinicaltrialsregister.eu/, EudraCT number 2019-002444-24.